Hirokazu Ogino
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 13
- Lung Cancer Research Studies 11
-
- Lung Cancer Treatments and Mutations 16
- Occupational and environmental lung diseases 10
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 8
- Pleural and Pulmonary Diseases 6
- Hepatology top 5%
-
- Immune cells in cancer 8
-
- Neuroendocrine Tumor Research Advances 4
- Co-authors
- Yasuhiko NishiokaSeiji YanoSaburo SoneMasaki HanibuchiHisanori UeharaSoji KakiuchiWei WangQi Li
- Journals
- Nature Communications (1 paper)Journal of Clinical Oncology (1 paper)The Journal of Immunology (3 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Hirokazu Ogino
49 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 551
- Pulmonary and Respiratory Medicine 580
- Hepatology 127
- Cancer Research 158
- Molecular Biology 521
Countries citing papers authored by Hirokazu Ogino
This map shows the geographic impact of Hirokazu Ogino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirokazu Ogino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirokazu Ogino more than expected).
Fields of papers citing papers by Hirokazu Ogino
This network shows the impact of papers produced by Hirokazu Ogino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirokazu Ogino. The network helps show where Hirokazu Ogino may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hirokazu Ogino, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 12 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 17 | |
| 8 | 2023 | 7 | |
| 9 | 2022 | 3 | |
| 10 | 2022 | 10 | |
| 11 | 2021 | 3 | |
| 12 | 2021 | 4 | |
| 13 | 2018 | 4 | |
| 14 | 2014 | 47 | |
| 15 | 2011 | 16 | |
| 16 | 2010 | 9 | |
| 17 | Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement | 2009 | 17 |
| 18 | 2009 | 27 | |
| 19 | Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutationsbreakdown → | 2008 | 513 |
| 20 | 2002 | 14 |
About Hirokazu Ogino
Hirokazu Ogino is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology, having authored 54 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Research Studies (11 papers), Occupational and environmental lung diseases (10 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Immune cells in cancer (8 papers), Pleural and Pulmonary Diseases (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). The work is most often cited by research in Oncology (551 citations), Pulmonary and Respiratory Medicine (580 citations) and Hepatology (127 citations). Hirokazu Ogino has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yasuhiko Nishioka, Seiji Yano, Saburo Sone, Masaki Hanibuchi, Hisanori Uehara, Soji Kakiuchi, Wei Wang, Qi Li, Kunio Matsumoto and Yasushi Yatabe. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.